Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ANVS 
Annovis Bio Inc (ANVS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: ANVS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13.75
1 Year Target Price $13.75
| 2 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -89.65% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 49.38M USD | Price to earnings Ratio - | 1Y Target Price 13.75 |
Price to earnings Ratio - | 1Y Target Price 13.75 | ||
Volume (30-day avg) 4 | Beta 1.61 | 52 Weeks Range 1.11 - 8.93 | Updated Date 11/4/2025 |
52 Weeks Range 1.11 - 8.93 | Updated Date 11/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.96 |
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.305 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -111.68% | Return on Equity (TTM) -365.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 26324009 | Price to Sales(TTM) - |
Enterprise Value 26324009 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.57 | Shares Outstanding 26114670 | Shares Floating 17065067 |
Shares Outstanding 26114670 | Shares Floating 17065067 | ||
Percent Insiders 11.85 | Percent Institutions 11.54 |
Upturn AI SWOT
Annovis Bio Inc
Company Overview
History and Background
Annovis Bio, Inc. is a clinical-stage drug platform company founded in 2008. It focuses on developing therapies for neurodegenerative diseases, such as Alzheimer's and Parkinson's disease.
Core Business Areas
- Drug Development: Developing and commercializing therapies for neurodegenerative diseases.
Leadership and Structure
Maria L. Maccecchini is the President and CEO. The company operates with a structure typical of a small biotechnology firm, focused on research and development.
Top Products and Market Share
Key Offerings
- Posiphen: Posiphen is Annovis Bio's lead drug candidate in clinical development for Alzheimer's and Parkinson's diseases. Market share data is unavailable, as the drug is not yet approved. Competitors include major pharmaceutical companies developing Alzheimer's and Parkinson's drugs: Biogen (BIIB), Eli Lilly (LLY), Roche (ROG), and AbbVie (ABBV).
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on neurodegenerative diseases is highly competitive and involves substantial research and development. It is characterized by high regulatory hurdles and long development timelines.
Positioning
Annovis Bio is a relatively small player focused on a novel approach to treating neurodegenerative diseases. Its competitive advantage lies in its unique mechanism of action targeting multiple toxic proteins.
Total Addressable Market (TAM)
The global market for Alzheimer's disease therapeutics is projected to reach billions of dollars. Annovis Bio is positioned to capture a portion of this TAM if Posiphen receives regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach
- Experienced leadership team
- Potential for disease-modifying treatment
Weaknesses
- Limited financial resources
- Reliance on single drug candidate
- High risk of clinical trial failure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into other neurodegenerative diseases
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- ROG
- ABBV
Competitive Landscape
Annovis Bio is an underdog against well established drug companies, but has a competitive advantage to the multi toxic protein mechanism of action.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily tied to clinical trial progress and securing funding.
Future Projections: Future growth depends on the successful development and commercialization of Posiphen.
Recent Initiatives: Focus on advancing clinical trials for Posiphen in Alzheimer's and Parkinson's diseases.
Summary
Annovis Bio is a high-risk, high-reward clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. Its success is contingent on the positive outcome of its clinical trials for Posiphen. The company faces significant competition and financial challenges, but has the potential to address a large unmet need in the treatment of Alzheimer's and Parkinson's diseases. They need to maintain tight control over spending as they do not make a profit.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The biotechnology industry is inherently risky, and Annovis Bio's future performance is uncertain.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Annovis Bio Inc
Exchange NYSE | Headquaters Malvern, PA, United States | ||
IPO Launch date 2010-02-12 | Founder, CEO, President & Executive Director Dr. Maria L. Maccecchini Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.annovisbio.com |
Full time employees 8 | Website https://www.annovisbio.com | ||
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.